At the start of 2020, buying marijuana stocks is one of the most challenging trades for growth investors. After a spectacular boom-and-bust cycle of 2019, there is too much uncertainty in the air about the world’s best marijuana stocks. After riding on the pot legalization wave in Canada, many producers are struggling to show that they can make this business…
Read More
Many pundits are predicting that after a rough 2019, cannabis stocks will bounce back in 2020. During 2019, the marijuana bubble burst, seeing many cannabis stocks plunge sharply over the course of the year, causing the industry’s largest exchange-traded fund (ETF), ETFMG Alternative Harvest ETF, to lose a whopping 35%, with its largest single holding Canopy Growth shedding the same…
Read MoreKali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today highlighted that its RespRx CBD formulation could offer treatment for coronavirus symptoms. KALY's CBD formulation has been developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions…
Read More
TFSAs are perfect vehicles for saving. All of your capital will grow tax free, and when it’s time for withdrawals, those are tax free, too. What kind of stocks should you be holding in a TFSA? There are several viable options. The biggest mistake is simply to hold cash. Mediocre returns essentially nullify your tax benefits. If you want to…
Read More
Nearly every pot stock doubled in value in 2018. Some quintupled in value. Last year was a different story. In 2019, any company related to marijuana was hit hard. Cannabis ETFs finished the year down more than 50%. The pullback has laid the groundwork for another bull run in 2020. Many investors have been scared off, but these are exactly…
Read MoreDALLAS, Jan. 27, 2020 /PRNewswire/ — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an anticipated increase in gross margins from the consolidation of its business structure and focus on its Cannabis Biopharmaceutical Technology. KALY has a U.S. Patented Cannabis Extraction Process and is developing treatments for various medical conditions. The technology has been valued at $50…
Read More
Talking about volatility in investing is often a one-sided conversation. In other words, most people expect a stock to go up or down, but typically in one direction. With the Canadian cannabis industry, any investor who has seen a stock chart of the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) will know that volatility on both ends of the spectrum has…
Read More
Last year was rough for pot investors. Most cannabis stocks fell by more than 50%. More than $10 billion in value was destroyed in a matter of months. Long gone were the days of 2018, when every pot stock was soaring to new heights. While the cannabis bear market left many investors scarred for life, it should’ve been expected. Every…
Read More
Boy, what a year 2019 was for investors in Canada’s new cannabis industry. The mood among many has certainly shifted, and the euphoria with which companies were gobbling each other up has abated. Horizons Marijuana Life Sciences Index ETF is now down 65% from its 52-week high in early 2019 (not its overall peak). Questions about where the bottom is remain, and…
Read More
Cannabis grower and leading distributor Aphria’s (TSX:APHA)(NYSE:APHA) stock price could continue to surge and outperform industry peers in 2020, and I’m maintaining my positive outlook and reiterating a buy recommendation on this marijuana firm. In a November 2019 post, and while discussing three potential buys for 2020, I likened the stock’s potential payoff to that on a cannabis lottery ticket.…
Read More